Valneva (NASDAQ:VALN) Announces Quarterly Earnings Results, Beats Estimates By $0.11 EPS

Key Points

• Valneva reported a quarterly earnings per share (EPS) of ($0.16), surpassing analysts' estimates by $0.11.
• The company has a market capitalization of $788.95 million and its shares opened at $9.27.
• Recent analyst ratings include Guggenheim lowering its price target from $15.00 to $14.00 while HC Wainwright maintained a "buy" rating with a $17.00 price target.

Valneva (NASDAQ:VALN - Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.11, Zacks reports. Valneva had a negative return on equity of 43.05% and a negative net margin of 43.08%.

Valneva Stock Performance

Shares of VALN opened at $9.27 on Tuesday. The business's 50 day moving average is $6.51 and its two-hundred day moving average is $6.62. Valneva has a 52-week low of $3.62 and a 52-week high of $9.15. The firm has a market cap of $788.95 million, a price-to-earnings ratio of -7.79 and a beta of 1.77. The company has a quick ratio of 2.12, a current ratio of 2.70 and a debt-to-equity ratio of 0.92.

Analyst Ratings Changes

VALN has been the topic of several recent research reports. Guggenheim reduced their price target on Valneva from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. HC Wainwright reissued a "buy" rating and set a $17.00 price target on shares of Valneva in a research report on Tuesday, April 15th.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.